[1] |
LI Shanshan, GU Jingwen, ZHANG Jing, YANG Haijing, LIU Wei, YU Yiqi, ZHANG Wenhong.
Design and evaluation of clinical trials of COVID-19 vaccine and monoclonal neutralizing antibody
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 190-197.
|
[2] |
TANG Jiawei, MENG Xiangzhe, SUN Xuemin, LI Yuexuan, LIU Xue, WEI Hong.
Role of vitamin D and ACE2 in COVID-19
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1292-1298.
|
[3] |
ZHENG Lichun, WANG Xiang, WANG Wenmei.
Management strategies and suggestions on stomatological clinical trials under the influence of epidemic
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 213-216.
|
[4] |
YU Tianyi, JIAO Guangyang, HUANG Doudou, CHEN Yong, XU Deduo, QIU Shi, CHEN Wansheng, ZHANG Feng, WANG Bolong.
Analysis of the effective components and mechanism of Yufang Fangji II for prevention of COVID-19 based on UHPLC-Q-TOF/MS and network pharmacology
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1127-1145.
|
[5] |
YIN Yujie, CHANG Liping.
Pharmacological research and clinical applications progress of Lianhua Qingwen capsules/granules in respiratory diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1174-1180.
|
[6] |
ZHANG Zhengfu, LI Meng, WANG Jianan.
Protection of subjects' legal rights, welfare and safety in clinical trials of COVID-19
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 421-425.
|
[7] |
QIN Qun, LIU Xiaobao, YANG Guoping, LI Zhuo, LI Kunyan, HUANG Zhijun, LIU Zhaoqian.
COVID-19:Emergency response measures for GCP in Hunan province under the first level response of major public health emergencies(2.0 Version)
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 323-328.
|
[8] |
XIANG Yuxia, ZENG Chan, HUANG Zhijun, WANG Xiaomin, ZHANG Zeyu, YANG Guoping.
Analysis of clinical trial registration information of COVID-19 in China
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 135-140.
|
[9] |
HU Ke.
New coronavirus pneumonia: Question and confusion
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 141-143.
|
[10] |
LI Hongpeng, ZHANG Liu, LI Qingyun.
Mechanism and advance of COVID-19 on immune related pathogenesis and immunotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1288-1294.
|
[11] |
GAO Jingshu, WANG Yu, QIN Huichao, ZHU Mengyi, WU Xiaoke.
Strategy on improving quality of study of triazavirin for 2019 novel coronary pneumonia (COVID-19) with features of "core data targeted"
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1171-1177.
|